Author: [email protected]

Release – Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Posted on by [email protected]

June 03, 2026

 Download as PDF

BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin will continue as Chief Financial Officer.

“James brings the right experience in the biopharma business as we’re accelerating the advancement of multiple clinical programs,” said Roger Kornberg, Ph.D., Chairman of Cocrystal Pharma. “We have known him for many years, and our management team and board are appreciative of his decision to join us as Chief Executive Officer.”

Mr. Sapirstein commented, “Cocrystal’s pipeline comprises transformative antivirals developed using its structure based drug discovery platform. We are well positioned with the right technology and team to create meaningful benefits for patients as well as our shareholders. The potential to address the need for new antivirals is highly motivating for me with my product development and launch background.”

Mr. Sapirstein has participated in or led 23 product launches. He has also driven numerous business development transactions. Mr. Sapirstein was Chief Executive Officer of Contravir Pharmaceuticals, served as the founding Chief Executive Officer of Tobira Therapeutics, and as Executive Vice President, Metabolic and Endocrinology, for Serono Laboratories.

Earlier in his career, he held senior marketing and commercialization positions, at Gilead Sciences and director of international marketing of the infectious disease division at Bristol Myers Squibb.

Mr. Sapirstein is a member of several industry boards and previously served as Chairman of BioNJ as well as Biotechnology Innovation Organization board member for more than a decade. He is also a founding member of the board of advisors of the Miami Biotech Collective.

About Cocrystal Pharma’s Structure-Based Drug Discovery Platform

Cocrystal Pharma is leveraging its structure based drug discovery platform technology to design next generation antiviral candidates that precisely target viral replication mechanisms. By binding to highly conserved regions of viral enzymes, the Company’s compounds aim to maintain potency against mutating strains while minimizing off target effects, offering potentially safer, broad spectrum antiviral solutions. This approach streamlines candidate identification and optimization, enabling more rapid progression of promising therapies with robust resistance and safety profiles.

The Company’s platform provides a three dimensional structure of inhibitor complexes at near-atomic resolution, providing immediate insight to guide Structure Activity Relationships. This helps identify novel binding sites and enables a rapid turnaround of structural information through highly automated X-ray data processing and refinement. This technology permits the development of novel broad spectrum antivirals.

About Cocrystal Pharma

Cocrystal Pharma Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Cocrystal employs unique structure based technologies to create viable antiviral drugs. For more information, visit www.cocrystalpharma.com.

Release – V2X to Generate Interest Expense Savings Through Successful Term Loan Repricing

Posted on by [email protected]
V2X (PRNewsfoto/V2X, Inc.)

June 03, 2026

RESTON, Va., June 3, 2026 /PRNewswire/ — V2X, Inc. (NYSE: VVX), today announced the successful repricing of its approximately $869 million First Lien Term Loan. The repricing improves the applicable interest rate to SOFR plus an applicable margin of 2.0%, with an additional 25 basis-point-reduction upon achieving specific corporate credit ratings of Ba3 (stable outlook) from Moody’s and BB (stable outlook) from S&P. The repricing also reduced the SOFR floor from 0.75% to 0.00%.

“This transaction immediately lowers our borrowing costs and positions us to realize interest savings as our financial profile continues to strengthen,” said Shawn Mural, Senior Vice President and Chief Financial Officer of V2X. “The repricing provides a 25-basis-point reduction in our applicable margin, with the opportunity for an additional 25-basis-point reduction upon achieving and maintaining specified credit ratings. These savings are expected to drive lower interest expense, enhance our cost of capital, and increase value for shareholders.”

With the closing on Friday May 29, 2026, V2X has now successfully repriced its First Lien Term Loan four times since October 2023.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact 
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
[email protected]
719-637-5773

Media Contact 
Angelica Spanos Deoudes
Senior Director, Corporate Communications
[email protected]
571-338-5195

Release – Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Posted on by [email protected]

PONTE VEDRA, Fla., June 03, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced its participation in the BIO International Convention 2026 Partnering Event (BIO 2026) taking place June 22-25, 2026, at the San Diego Convention Center.

The Company’s executive management team will host partnering meetings to discuss development and commercialization opportunities for its differentiated pipeline, headlined by CAD-1005, a Phase 3-ready 12-lipoxygenase (12-LOX) inhibitor being investigated for the treatment of patients with Heparin-Induced Thrombocytopenia (HIT), and tecarfarin, a late-stage oral Vitamin K antagonist (VKA) for being investigated for the treatment of patients with conditions for which current anticoagulation profiles are ineffective or suboptimal.

“BIO 2026 comes at a pivotal moment for Cadrenal as we prepare to initiate our Phase 3 registration trial for CAD-1005,” said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. “With Orphan Drug and Fast Track designations from the FDA, we believe we are uniquely positioned to address the significant unmet need in HIT, a condition where no new therapies have been approved in over two decades. We look forward to engaging with potential partners who share our vision of the potential to bring this breakthrough mechanism to patients.”

Highlighting CAD-1005: A Potential First-in-Class Solution for HIT
At the forefront of Cadrenal’s portfolio is CAD-1005, the only selective 12-LOX inhibitor known to us to be currently in clinical development. CAD-1005 is being investigated to target the root cause of HIT-a severe, immune-mediated reaction to heparin that causes life-threatening blood clots and low platelet counts. Unlike current therapies that only reduce the risk of thrombotic complications, CAD-1005 is being investigated to interrupt the immune signaling feedback loop that drives the development and persistence of HIT.

The Company recently completed an End-of-Phase 2 (EOP2) meeting with the FDA, which provided guidance on the registration path for a single pivotal Phase 3 trial. This follows Phase 2 data demonstrating that CAD-1005 could reduce thrombotic events in patients with HIT.

Unlocking the Potential of the 12-LOX Platform
Beyond HIT, Cadrenal is leveraging the BIO 2026 partnering forum to explore broader applications for its proprietary 12-LOX inhibitor platform. Emerging research indicates that 12-LOX may play a central role in inflammatory signaling across high-impact disease areas, including atherosclerosis, microvascular thrombosis, and metabolic conditions such as diabetes and obesity. Additionally, 12-LOX is a potential target for therapy and prevention of cancer.

The Company’s platform represents a novel approach to modulating inflammation without the broader systemic suppression associated with traditional anti-inflammatory agents. Cadrenal aims to identify strategic collaborations to accelerate the development of its second-generation oral 12-LOX inhibitors (CAD-2000) for these chronic, large-market indications.

Tecarfarin: A Potentially Superior Anticoagulant for Complex Cases
Cadrenal will also present opportunities for tecarfarin, its late-stage oral anticoagulant. Tecarfarin is being designed with the goal of being uniquely metabolized in ways that avoid the drug-drug interactions and renal clearance issues common with warfarin and direct oral anticoagulants (DOACs). Tecarfarin has already received FDA Orphan Drug and Fast Track designations for two specific high-risk populations – patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs).

About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is being researched as a first-in-class 12-LOX inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also in development for chronic indications.

The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and those with left ventricular assist devices, and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings.

Release – MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

Posted on by [email protected]

June 03, 2026 9:45am EDT

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA

FDA-cleared IND updates detail latest efficacy data and enriched manufacturing protocols

CHICAGO, June 03, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared an amendment to update its investigational new drug (IND) application which enables MAIA to open U.S. enrollment for the expansion of the Phase 2 THIO-101 trial of its lead candidate, ateganosine, as a treatment for advanced non-small cell lung cancer (NSCLC). Ateganosine is a novel dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Ateganosine sequenced with a monoclonal antibody checkpoint inhibitor is being evaluated as a therapy for patients in ongoing Phase 2 and Phase 3 clinical trials.

MAIA obtained FDA clearance of its updated IND highlighting MAIA’s improved efficiencies to its manufacturing capabilities, including new manufacturers, formulation and storage conditions for ateganosine, and MAIA is now cleared to enroll patients in the U.S. for the expansion of the Phase 2 THIO-101 study of patients receiving advanced third-line (3L) NSCLC treatment. In addition to the U.S., the THIO-101 study is ongoing at 44 clinical sites in six countries. MAIA recently activated its first U.S. clinical site at Summit Medical Group in New Jersey.

In July 2025, the FDA granted Fast Track designation for ateganosine for the treatment of NSCLC. This designation allows for more frequent FDA communication, potential rolling review, and eligibility for Accelerated Approval and Priority Review. The additional data from the expansion studies may further support a filing for FDA Accelerated Approval.

“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two years for eight patients treated with ateganosine in Parts A and B of THIO-101. We believe this bodes well for Parts C and D evaluations which are specific to third-line treatment care only, where the unmet need for improved clinical outcomes is most urgent.”

K. Robinson Lewis, Senior Vice President and Head of Regulatory and Quality for MAIA, commented, “We are excited about the prospects for our U.S. trials following FDA clearance of our amended IND. The unmet need for effective third-line NSCLC treatments is widespread in the U.S. Based on strong clinical data documented so far, we are confident in the potential of our therapy to address this significant and substantially underserved patient population.”

In parallel with THIO-101, MAIA is actively screening and enrolling patients in a pivotal Phase 3 clinical trial, THIO-104, designed to assess overall survival for ateganosine sequenced with a CPI compared to investigator’s choice of chemotherapy in a 1:1 randomization of up to 300 third-line NSCLC patients.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Bitcoin Falls Below $67,000 as Strategy Records First Sale Since 2022

Posted on by [email protected]

Bitcoin extended its recent losses Wednesday, dropping more than 2% to hover around $66,000 as investors processed a development that, while numerically small, carries significant psychological weight for the entire digital asset market. Strategy, the enterprise software company turned Bitcoin treasury vehicle formerly known as MicroStrategy, disclosed it had sold 32 Bitcoin tokens — its first sale since 2022 — marking a notable departure from the relentless accumulation strategy that made founder Michael Saylor one of the most vocal and influential advocates for institutional Bitcoin ownership.

The sale itself is a rounding error relative to Strategy’s holdings. The company still controls more than 843,000 Bitcoin, making it by far the largest corporate holder of the asset in the world. But in a market that has treated Saylor’s buy-and-hold conviction as a psychological floor, even a fractional departure from that posture sent a signal that traders responded to immediately. Bitcoin had already been under pressure heading into the week, and the disclosure accelerated the move lower.

Where the Technical Picture Stands

Analysts are now watching $65,000 as the next meaningful support level. David Morrison, senior market analyst at Trade Nation, noted that a sustained break below that threshold would raise the probability of a revisit to the February low of approximately $60,000. That level represents the cycle’s prior support floor and a breach of it would represent a new leg lower in what has already been a significant drawdown from Bitcoin’s highs above $100,000 earlier in this cycle.

Compass Point analyst Ed Engel added a more forward-looking interpretation, pointing to data showing that 26% of Bitcoin sales over the past 30 days came from investors who originally purchased the token at prices above $90,000. This cohort, described as “top buyers,” had shown unusual resilience throughout the bear market, holding through significant paper losses without liquidating. The fact that they are now selling is being interpreted by some analysts as a classic late-stage capitulation signal. Engel stated directly that the data makes him more confident that Bitcoin’s bear market is in its late stages.

The Small Cap Exposure

For investors tracking publicly traded companies with direct Bitcoin exposure, the price decline is not an abstraction. Bitcoin miners operating in the small and microcap space, including names like Riot Platforms, Marathon Digital, CleanSpark, and IREN, generate revenue directly tied to the value of the Bitcoin they produce and hold on their balance sheets. A sustained move toward $60,000 would compress mining economics, reduce treasury values, and put pressure on operating margins that are already sensitive to energy cost fluctuations.

Beyond the miners, a growing cohort of smaller public companies has adopted Bitcoin treasury strategies modeled on the Strategy playbook, accumulating Bitcoin as a primary balance sheet asset. For those companies, Bitcoin’s price trajectory is not a peripheral concern. It is the central variable in their financial story.

The late-stage capitulation thesis is worth monitoring carefully. If Engel’s read is correct, the worst of the selling may be closer to the end than the beginning. But until Bitcoin establishes a clear floor above $65,000, the near-term path for crypto-exposed small cap equities remains uncertain.

America’s Commercial Lunar Economy Just Got Its Most Important Infrastructure Deal Yet

Posted on by [email protected]

The race to build permanent infrastructure on the Moon has a new and more serious player. Voyager Technologies (NYSE: VOYG), a Denver-based defense technology and space solutions company, announced Tuesday it has signed a definitive agreement to acquire Astrobotic Technology, the Pittsburgh-based commercial lunar logistics and robotics company, for up to approximately $300 million in a combination of cash and stock. The deal is expected to close by early July 2026, subject to customary regulatory approvals.

For a company that has been quietly assembling a full-stack lunar infrastructure portfolio, the Astrobotic acquisition is the piece that makes the entire architecture operational.

What Astrobotic Brings to the Table

Founded in 2007 as a Carnegie Mellon University spinout, Astrobotic has spent nearly two decades building the hardware, software, and operational expertise required to deliver payloads to the lunar surface reliably and repeatably. The company has secured more than $600 million in NASA and Department of Defense contracts and holds the distinction of having launched America’s first commercial lunar lander. Its core product portfolio includes the Peregrine lander for smaller payload missions, the Griffin lander for larger surface delivery operations, and LunaGrid, a solar power distribution system designed to provide sustained electricity on the lunar surface.

That last element matters as much as the landers. A permanent human presence on the Moon requires more than transportation. It requires power infrastructure that can sustain life, operations, and scientific activity across lunar day-night cycles that last approximately two Earth weeks each. LunaGrid is purpose-built for exactly that requirement.

Astrobotic’s Moon Base headquarters in Pittsburgh will become the center of Voyager’s lunar program following close, with the company’s facility in Mojave also continuing operations.

The Full Stack Voyager Is Building

The Astrobotic acquisition does not stand alone. Voyager has been executing a deliberate vertical integration strategy across the lunar infrastructure stack, and this deal slots directly into that roadmap. The combined company will now span lunar mission management, communications and propulsion, surface delivery through Peregrine and Griffin, surface power through LunaGrid, long-duration habitation through its prior strategic investment in Max Space’s expandable habitat architecture, dust mitigation through Voyager’s proprietary clear-dust repellent coating technology, and in-situ resource production.

That is a comprehensive end-to-end lunar capability assembled through targeted acquisitions rather than organic development alone. The strategic efficiency of that approach is notable for a company operating in the small cap space.

The acquisition directly supports NASA’s Artemis program and Administrator Jared Isaacman’s stated commitment to establishing a permanent American presence on the Moon by 2028. Astrobotic’s Griffin Mission One, recently designated NASA’s Moon Base II mission, is proceeding on schedule and will transition fully under Voyager at close.

Why This Deal Matters for Small Cap Space Investors

The commercial lunar economy is not a distant concept. It is a funded, contracted, timeline-driven government priority with hundreds of millions of dollars already flowing to companies like Astrobotic. What has been missing is the kind of vertically integrated commercial operator capable of managing every layer of a sustained lunar presence. Voyager is systematically becoming that operator.

With SpaceX’s June 12 IPO approaching at a targeted $1.75 trillion valuation and the broader space infrastructure sector attracting record institutional attention, consolidation among smaller space technology companies is accelerating. Voyager’s acquisition of Astrobotic is precisely the kind of strategic move that positions a small cap defense and space company for the contracts, partnerships, and government relationships that will define the commercial lunar economy over the next decade.

Power Metallic Mines Inc. (PNPNF) – Advancing Lion Resource Growth and Expanding District Exploration

Posted on by [email protected]


Tuesday, June 02, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Recent Drill Results. Power Metallic reported strong drill results from the Lion deposit, including high-grade near-surface copper intercepts, while metallurgical testing demonstrated excellent recoveries from lower-grade material. The results support resource growth potential and enhance confidence ahead of the upcoming NI 43-101 Mineral Resource Estimate (MRE) expected in late July and a Preliminary Economic Assessment (PEA) in December 2026.

Summer Exploration and Drilling Program. Power Metallic has expanded its summer exploration program at the Nisk Project with advanced geophysical surveys and more than 30,000 meters of planned drilling. The program is designed to identify extensions of known mineralization and generate new discovery targets across the company’s Nisk land package while supporting future resource growth.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Summit Midstream Corp (SMC) – Inaugural Stock Repurchase Program

Posted on by [email protected]


Tuesday, June 02, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Stock Repurchase Authorization. Summit Midstream Corporation announced that its Board of Directors has authorized the company’s first stock repurchase program, allowing for the repurchase of up to $35 million of outstanding common stock. As of May 8, shares outstanding were 20.3 million, including 13.8 million common shares and 6.5 million Class B common shares.

Terms of the Program. Summit may repurchase shares through open market transactions, privately negotiated purchases, block trades, or other methods permitted under applicable securities laws. Repurchase activity will depend on market conditions, share price, debt covenant compliance, and other factors. The program has no expiration date, does not require the company to buy back any specific number of shares, and may be suspended or terminated at any time.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MAIA Biotechnology (MAIA) – Phase 3 THIO-104 Trial Design Presented At ASCO

Posted on by [email protected]


Tuesday, June 02, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 3 THIO-104 Design Is Consistent With Expectations. MAIA presented a poster on May 31, 2026, at the Annual ASCO (American Society of Clinical Oncology) Meeting. The poster detailed the design of its ongoing Phase 3 THIO-104 trial that tests ateganosine (aka THIO) in combination with the checkpoint inhibitor cemiplimab as a third-line treatment for patients with non-small cell lung cancer (NSCLC) who have become resistant to CPI treatment and chemotherapy.

Trial Design Is Consistent With Results From Phase 2 THIO-101 Trial. The patient population, selected dose, and combination regimen with Ateganosine 180mg and cemiplimab (Libtayo, from Regeneron) are the same as those in the Phase 2 THIO-101 study. At last analysis as of June 30, 2025, this regimen showed a median observed Overall Survival (OS) of 17.8 months, compared with published studies reporting an OS of 5.8 months.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

V2X (VVX) – Raising Price Target

Posted on by [email protected]


Tuesday, June 02, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Raising Price Target. With VVX share moving north of our $72 price target, we are increasing our target to $92 while maintaining our Outperform rating. At our new price target, VVX shares would trade at 0.8x our projected 2026 revenue, 11x our projected 2026 adjusted EBITDA, and 15.5x our projected 2026 adjusted EPS. These multiples are in line with VVX’s key competitors. VX shares are up approximately 52% y-t-d, versus an 11% rise for the S&P 500.

Overhang Removed. With American Industrial Partners’ May 2026 sale of approximately 2 million VVX shares, the firm is essentially out of V2X shares, completing a two-year process as AIP liquidated its 61%+ ownership stake in V2X acquired in the merger of Vectrus and Vertex, removing an ongoing overhang of stock, in our view. An entity affiliated with Vertex Aerospace did, however, continue to beneficially own 375,420 shares, or approximately 1.2%, of V2X’s outstanding common stock following the most recent share sale.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Greenwich LifeSciences, Inc. (GLSI) – Additional Phase 3 FLAMINGO-01 Data Presented At ASCO Meeting

Posted on by [email protected]


Tuesday, June 02, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Additional Data Presented At ASCO. Greenwich LifeSciences presented an abstract and poster at the ASCO Annual Meeting.  The data assessed non-HLA-A*02 patients in the open-label arm after six monthly doses of GLA-100. The data show statistically significant injection site reaction (ISR) and immune response at baseline, with increases over time.

Patients Were Evaluated After Initial Immune Stimulation. Patients received the Primary Immunization Series (PIS), consisting of six vaccinations over the first six months of the trial. The fourth, fifth, and sixth vaccinations showed a significant increase in the percentage of patients showing an ISR compared to baseline. Of the 247 patients enrolled, 208 had both baseline vaccination and assessments at 4, 5, or 6 months.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Aurania Resources (AUIAF) – First Tranche of Private Placement Closed

Posted on by [email protected]


Tuesday, June 02, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Private Placement Financing. Aurania Resources Ltd. closed the first tranche of its previously announced non-brokered private placement, raising C$678,263.76 through the issuance of 3,768,132 units at C$0.18 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of C$0.35 per share for a period of 24 months following the close of the first tranche. The financing is part of a larger offering of up to 8,333,333 units that could generate total gross proceeds of up to approximately C$1.5 million. Dr. Keith Barron, Aurania’s Chief Executive Officer and President, participated in the financing by acquiring 1,666,666 units.

Use of Proceeds. The net proceeds will be used to fund exploration at the Thor’s Valley epithermal gold project in Iceland, support the Balangero nickel-cobalt tailings retreatment project in Italy, and fund general working capital. In May, Aurania closed its option agreement with St-Georges Eco-Mining Corp (CSE: SX) and its wholly owned subsidiary, Iceland Resources, to work collaboratively to define and execute a phased exploration program at the Thor’s Valley gold project to advance the project toward initial modern resource definition.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Anthropic Just Filed for an IPO at $965 Billion. The AI Capital Cycle Has Entered a New Phase

Posted on by [email protected]

The artificial intelligence industry’s march toward public markets just crossed a threshold that Wall Street has been watching closely for months. Anthropic, the San Francisco-based AI company behind the Claude family of large language models, confirmed Monday it has submitted a confidential draft S-1 registration statement to the Securities and Exchange Commission — the first formal legal step toward an initial public offering.

The filing contains no share count, no price range, and no confirmed listing date. Under the confidential process, full financial disclosures remain private until the SEC completes its review, at which point Anthropic will decide whether to proceed based on market conditions. A public debut as early as Fall 2026 is widely expected.

What is known is the valuation at which Anthropic is entering this process. Just days before the filing, the company closed a $65 billion Series H funding round co-led by Altimeter Capital, Dragoneer, Greenoaks, Sequoia Capital, Capital Group, Coatue, and D1 Capital Partners, pushing its post-money valuation to approximately $965 billion. That figure places Anthropic ahead of rival OpenAI in private market valuation and positions it at the front of the most consequential IPO pipeline in the history of the technology industry.

The Company Behind the Filing

Anthropic was founded in 2021 by Dario Amodei, Daniela Amodei, and several colleagues who departed OpenAI. The company has built its business on the Claude model family, which spans consumer, enterprise, and frontier AI applications, and has established major compute agreements with Amazon, Google, and Broadcom. Claude is available across AWS, Google Cloud, and Microsoft Azure, giving the company distribution through the three largest cloud platforms simultaneously. The company’s CFO described the latest funding round as support to serve the demand for Claude while expanding research, compute capacity, and product partnerships.

The Broader IPO Context

Anthropic’s filing lands inside what is shaping up to be the most concentrated AI IPO season in market history. Cerebras Systems debuted on Nasdaq in May, surging nearly 90% on its first day of trading in the largest US tech IPO since Uber in 2019. SpaceX’s roadshow begins Thursday with the June 12 Nasdaq listing targeting a $1.75 trillion valuation and a $75 billion raise. OpenAI is expected to follow Anthropic to the SEC with its own filing in the weeks ahead.

The cumulative implied valuation of these four AI companies alone approaches $4 trillion. That number represents an entirely new category of public market listing, and its effect on sentiment, capital allocation, and sector multiples across the AI ecosystem is already being felt.

What It Means for Smaller AI Companies

For investors in the sub-$2 billion AI space, the Anthropic filing matters for a specific reason. Cerebras and Nvidia represent the hardware and infrastructure layer of AI. Anthropic and OpenAI represent the model and software layer. When both layers of the AI stack are simultaneously achieving historic public market valuations, the effect on smaller companies operating across either layer is historically consistent: institutional capital broadens its reach, multiples expand across the sector, and the companies that were already building real products in the space benefit from the rising tide.

The IPO window that cracked open with Cerebras in May is now wide open. Anthropic just made sure of it.